Drug
Dexamethasone 20mg
Dexamethasone 20mg is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
completed267%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
completed
Steroid Injection for Sickle Cell Arthropathy Pain Therapy
NCT05983055
withdrawnphase_1
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
NCT05205252
completedphase_2
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
NCT03242460
Clinical Trials (3)
Showing 3 of 3 trials
NCT05983055
Steroid Injection for Sickle Cell Arthropathy Pain Therapy
NCT05205252Phase 1
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
NCT03242460Phase 2
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3